Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Microfibrillar-associated protein 5 (MFAP5) mRNA 3' untranslated region (3' UTR) is a regulatory segment of the MFAP5 transcript that governs the stability and translation of the encoded protein. MFAP5, also known as MAGP2, is a secreted glycoprotein essential for the assembly of microfibrils and the structural integrity of the extracellular matrix (UniProt P55001). This 3' UTR contains specific binding sites for microRNAs, such as miR-200c and miR-133a, which act as post-transcriptional repressors to maintain physiological levels of MFAP5 (PubMed: 25252155). In several cancers, including ovarian and breast cancer, the dysregulation of this region or the loss of its targeting microRNAs leads to MFAP5 overexpression in the tumor stroma (PubMed: 24510013). High levels of MFAP5 promote aggressive tumor phenotypes by stimulating angiogenesis and activating the Notch and TGF-beta signaling pathways (PubMed: 20406990). Consequently, the MFAP5 mRNA 3' UTR is an attractive target for RNA-based therapeutics like antisense oligonucleotides (ASOs) or miRNA mimics designed to silence the gene (PubMed: 30104345). Such interventions aim to normalize the tumor microenvironment and inhibit metastatic progression. Preclinical studies have demonstrated that targeting this region can enhance the sensitivity of cancer cells to chemotherapy. Therapeutic challenges include the efficient delivery of RNA-targeting agents to the stroma and minimizing off-target effects on other microfibril-associated proteins.
Antisense inhibition or RNA interference targeting the 3' untranslated region to reduce protein translation and promote mRNA degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microfibrillar-associated protein 5 mRNA 3' untranslated region (MFAP5 mRNA 3' UTR).